Phathom Pharmaceuticals, Inc. Common Stock
$7.48
-$0.27 (-3.48%)
$7.46Day Range$7.76
Key Statistics
Market Cap
$605.14M
Shares Outstanding
80.9M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 25, 2019
Round Lot
100
Locale
US
Trading Data
Day Open
$7.63
Day High
$7.76
Day Low
$7.46
Volume
1.79M
VWAP
$7.51
Prev Close
$7.75
Transactions
--
Acc. Volume
--
About Phathom Pharmaceuticals, Inc. Common Stock
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
PHARMACEUTICAL PREPARATIONSSIC 2834371 employees100 CAMPUS DRIVE,, FLORHAM PARK, NJ, 07932(877) 742-8466IPO Oct 25, 2019US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001783183
- Composite FIGI
- BBG00P5B2S19
- Share Class FIGI
- BBG00P5B2S73
- Ticker Root
- PHAT
- SIC Code
- 2834
About Phathom Pharmaceuticals, Inc. Common Stock (PHAT) Stock
Phathom Pharmaceuticals, Inc. Common Stock (PHAT) closed the 2026-09-18 session at $7.48, down 3.48% versus the previous close (-0.27). The stock opened at $7.63 and traded between $7.46 and $7.76 during that session. Session trading volume was 1.8M shares. The volume-weighted average price (VWAP) is $7.51.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Phathom Pharmaceuticals, Inc. Common Stock has a market capitalization of $605.1 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. PHAT is listed on the XNAS exchange. The company employs approximately 371 people. Phathom Pharmaceuticals, Inc. Common Stock is headquartered in FLORHAM PARK, NJ. The recorded listing date is 2019-10-25.
On this page you can find market PHAT stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.